Difference between revisions of "Team:EPFL"

Line 51: Line 51:
 
           </div>
 
           </div>
  
            <div class="p-5 rounded bg-primary">
+
          <div class="p-5 rounded bg-primary">
              <a href="#abstract" class="tongue tongue-bottom scroll-me"><i class="fas fa-angle-down"></i></a>
+
            <a href="#abstract" class="tongue tongue-bottom scroll-me"><i class="fas fa-angle-down"></i></a>
            </div>
+
          </div>
  
 
         </div>
 
         </div>
Line 64: Line 64:
 
       <div class="container">
 
       <div class="container">
 
         <div class="mb-5 text-center">
 
         <div class="mb-5 text-center">
           <h3 class="heading h3">Project Timeline</h3>
+
           <h3 class="heading h3">This is CAPOEIRA</h3>
        </div>
+
        <div class="row justify-content-center">
+
          <div class="col-lg-12">
+
            <img width="100%" src="https://static.igem.org/mediawiki/2018/8/8d/T--EPFL--desc.svg">
+
          </div>
+
        </div>
+
 
+
 
+
        <div class="text-center mt-4">
+
          <p class="lead lh-180">Ultimately, CAPOEIRA trains the immune system to retaliate! </p>
+
 
         </div>
 
         </div>
  
 
       </div>
 
       </div>
 +
      <img width="100%" src="https://static.igem.org/mediawiki/2018/8/8d/T--EPFL--desc.svg">
 
     </section>
 
     </section>
  

Revision as of 18:21, 12 October 2018

iGEM EPFL 2018

CAPOEIRA

Cancer Personalized Encapsulin Immunotherapy and Relapse Assay

Learn more about our project

What is CAPOEIRA ?

While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to retaliate!

This is CAPOEIRA